Introduction
A new oral delivery system, gastrointestinal mucoadhesive patch system (GI-MAPS) has been developed to overcome the problem of very low oral bioavailabilty of peptide/protein drugs. In our previous study, GI-MAPS preparations had improved the oral bioavailabilty of a model protein drug, granulocyte colonystimulating factor (G-CSF) in beagle dogs. Therefore, the evaluation of the efficiency of GI-MAPS as a new oral delivery system was studied in human volunteers.
Methods

GI-MAPS
preparations: GI-MAPS preparations were composed of three layers: 1) backing layer, made of waterinsoluble polymer, ethylcellulose (EC), was prepared spreading 20% w/v EC solution on a teflon plate and dried at room temperature 2) adhesion sitecontrolling layer (enteric polymer membrane) was prepared from 20% w/v Eudragit L 100 by using the same method and 3) mucoadhesive drugcarrying layer prepared by mixing caffeine (50 mg), sodium salicylate (40 mg), HCO-60 (150 mg), 0.5 N NaOH (100 ill), deionized (DI) water (400111) 
Discussion
The increase in AUC and MRTi of salivary caffeine excretion rate is ascribed to the increased resident time of GI-MAPS at the absorption membrane as a result of bioadhesion. The mucoadhesive polymer, Carbopol, was thought to form gel structure in the small intestine and adhere to the intestinal wall. The prolonged residence time of GI-MAPS by sticking to the mucus layer at the site of absorption resulted in high drug concentration gradient between the system and the enterocytes thereby increasing the drug diffusion through trans cellular and paracellular routes. The lower AUC and MRTi values obtained under fed state study might be explained by the complexation of the mucoadhesive polymer with food contents. The increase in pH of GI tract after food intake also might have influenced the surface charge of both mucus membrane and polymer and it might have affected the degree of hydration and viscosity of mucoadhesive polymer that could reduce the adhesive strength between mucus membrane and polymer.
Conclusions 1) Significantly higher AUC and MRTi with GI-MAPS than with the control establish the superiority of GI-MAPS as a oral drug deliver system. 2) Food intake may affect the delivery efficiency of GI-MAPS.
